David A. Siegel Dyne Therapeutics, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$273 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$267 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$155 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$145 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.76B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...